October 12th, 2026AAO 2026: A surf and turf approach to refractive IOL counselingDavid F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.Read more
October 12th, 2026AAO 2026: What the first whole eye transplant has taught surgeonsVaidehi Dedania, MD, shared what the first whole eye transplant revealed about reperfusion, retinal cells, and sight.Read more
October 12th, 2026AAO 2026: Can’t-miss uveitis diagnoses every clinician should knowTimothy Janetos, MD, outlined can’t-miss uveitis diagnoses, warning signs, and why every new patient needs dilation.Read more
October 11th, 2026AAO 2026: MCO-010 sustains vision gains in RP through 4 yearsKenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.Read more
October 11th, 2026AAO 2026: Inside an ophthalmic medical mission to ArmeniaJohn A. Hovanesian, MD, discusses the Armenian Eyecare Project’s annual trip, from preparation and surgery to teaching and student involvement.Read more
October 11th, 2026AAO 2026: Elegrobart reduces proptosis in active thyroid eye diseaseAt AAO 2026, Michael T. Yen, MD, reviewed REVEAL-1 efficacy and hearing safety data for subcutaneous elegrobart in active TED.Read more
October 11th, 2026AAO 2026: New trials target optic neuritis treatment questionsJohn J. Chen, MD, PhD, of Mayo Clinic discusses how NMOSD and MOGAD antibodies are changing optic neuritis care and the two trials now enrolling.Read more
October 11th, 2026AAO 2026: Kamuvudine K8 slows geographic atrophy growth in phase 2Liangbo Linus Shen, MD, shared phase 2 data showing kamuvudine K8 reduced geographic atrophy growth by 54%.Read more